Celsion Corp (CLSN) 3.25 $CLSN
Celsion Corporation to Hold Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014 Conference Call (Conference Code: 8283269) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Mon Jul 28, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of June 30, 2014, the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. The Hazard Ratio at this analysis is 0.639 (95% CI 0.419 - 0.974) with a p-value of 0.037.
Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:51AM CDT
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.
Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer
PR Newswire - Thu Jul 24, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients enrolled and treated, 10 were eligible for evaluation of efficacy. Based on data available to date, 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).
Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU
PR Newswire - Mon Jul 21, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that its ongoing collaboration with Dr. Costas Arvanitis of Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, has been expanded through the recent award of a $1 million Career Development Award from the National Institutes of Health's Center for Biomedical Imaging and Bioengineering (NIBIB). The grant will support preclinical studies evaluating ThermoDox®, the Company's heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumors. The grant, titled "Controlled Delivery and Release of Chemotherapy in Brain Tumors with FUS" provides on average of $200,000 in annual funding for five years, and will be used to advance preclinical development of ThermoDox® for the treatment of brain cancers, including GBM, under the Company's January 2014 collaboration with Brigham and Women's Hospital, Harvard Medical School.
Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Jul 15, 10:34AM CDT
What:
Celsion Corporation Announces Commercialization of Reagent Products
PR Newswire - Tue Jul 15, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced initiation of sales of its proprietary reagent products for life science research. Celsion's reagent products are based on its newly acquired proprietary delivery platform technologies, TheraPlas(TM) and TheraSilence(TM). TheraPlas(TM) and TheraSilence(TM) are designed for optimal transfection (intra-cellular delivery) of plasmid DNA and RNA into human (and other mammalian) cells.
Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014
PR Newswire - Mon Jul 14, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY.
Celsion Corporation Completes Acquisition of EGEN, Inc.
PR Newswire - Fri Jun 20, 8:00AM CDT
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes EGEN's Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas(TM) for delivery of DNA and mRNA, TheraSilence(TM) for delivery of RNA, and RAST(TM) for Cell Enabled Expression and Secretion of RNA.
Celsion (CLSN) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 10:21AM CDT
Celsion (CLSN) Enters Overbought Territory
Celsion announces completion of second USD5m tranche pursuant to loan facility with Hercules Technology Growth Capital
M2 - Wed Jun 11, 4:31AM CDT
Drugs company Celsion (NasdaqCM:CLSN) revealed on Tuesday the completion of its second USD5m tranche with Hercules Technology Growth Capital (NYSE:HTGC).
Celsion Closes Second $5 Million Tranche under Loan Facility Agreement with Hercules Technology Growth Capital
PR Newswire - Tue Jun 10, 9:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced that it has closed the second $5 million tranche under its $20 million Loan and Security Agreement dated as of November 25, 2013 with Hercules Technology Growth Capital, Inc. (NYSE: HTGC). The proceeds will be used to fund the $3.4 million upfront cash payment associated with Celsion's acquisition of EGEN, Inc., which was announced separately today, as well as Celsion's transaction costs associated with the EGEN transaction.
Celsion Corporation to Acquire EGEN, Inc.
PR Newswire - Tue Jun 10, 6:30AM CDT
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas(TM) for delivery of DNA and mRNA, TheraSilence(TM) for delivery of RNA, and RAST(TM) for Cell Enabled Expression and Secretion of RNA.
Update on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:00PM CDT
Celsion (CLSN) received regulatory clearance to initiate the OPTIMA study on ThermoDox.
Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Wed May 21, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan, Hong Kong, South Korea and Canada. The OPTIMA Study is the Company's planned global pivotal, double-blind, placebo-controlled study evaluating ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA), in primary liver cancer, also known as hepatocellular carcinoma (HCC).
Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update
PR Newswire - Thu Mar 13, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
PR Newswire - Thu Mar 06, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2013 financial results at 11:00 a.m. EST on Thursday, March 13, 2014. To participate in the call, interested parties may dial 1-888-572-7033 (Toll-Free/North America) or 1-719-325-2469 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2013 Conference Call (Conference Code: 6632100) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer
PR Newswire - Thu Feb 27, 3:05PM CST
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). These data are consistent with the previously reported positive Phase 1 data in RCWBC.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Celsion Corporation to Hold Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014 Conference Call (Conference Code: 8283269) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Mon Jul 28, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of June 30, 2014, the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. The Hazard Ratio at this analysis is 0.639 (95% CI 0.419 - 0.974) with a p-value of 0.037.
Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:51AM CDT
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.
Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer
PR Newswire - Thu Jul 24, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients enrolled and treated, 10 were eligible for evaluation of efficacy. Based on data available to date, 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).
Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU
PR Newswire - Mon Jul 21, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that its ongoing collaboration with Dr. Costas Arvanitis of Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, has been expanded through the recent award of a $1 million Career Development Award from the National Institutes of Health's Center for Biomedical Imaging and Bioengineering (NIBIB). The grant will support preclinical studies evaluating ThermoDox®, the Company's heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumors. The grant, titled "Controlled Delivery and Release of Chemotherapy in Brain Tumors with FUS" provides on average of $200,000 in annual funding for five years, and will be used to advance preclinical development of ThermoDox® for the treatment of brain cancers, including GBM, under the Company's January 2014 collaboration with Brigham and Women's Hospital, Harvard Medical School.
Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Jul 15, 10:34AM CDT
What:
Celsion Corporation Announces Commercialization of Reagent Products
PR Newswire - Tue Jul 15, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced initiation of sales of its proprietary reagent products for life science research. Celsion's reagent products are based on its newly acquired proprietary delivery platform technologies, TheraPlas(TM) and TheraSilence(TM). TheraPlas(TM) and TheraSilence(TM) are designed for optimal transfection (intra-cellular delivery) of plasmid DNA and RNA into human (and other mammalian) cells.
Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014
PR Newswire - Mon Jul 14, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY.
Celsion Corporation Completes Acquisition of EGEN, Inc.
PR Newswire - Fri Jun 20, 8:00AM CDT
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes EGEN's Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas(TM) for delivery of DNA and mRNA, TheraSilence(TM) for delivery of RNA, and RAST(TM) for Cell Enabled Expression and Secretion of RNA.
Celsion (CLSN) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 10:21AM CDT
Celsion (CLSN) Enters Overbought Territory
Celsion announces completion of second USD5m tranche pursuant to loan facility with Hercules Technology Growth Capital
M2 - Wed Jun 11, 4:31AM CDT
Drugs company Celsion (NasdaqCM:CLSN) revealed on Tuesday the completion of its second USD5m tranche with Hercules Technology Growth Capital (NYSE:HTGC).
Celsion Closes Second $5 Million Tranche under Loan Facility Agreement with Hercules Technology Growth Capital
PR Newswire - Tue Jun 10, 9:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced that it has closed the second $5 million tranche under its $20 million Loan and Security Agreement dated as of November 25, 2013 with Hercules Technology Growth Capital, Inc. (NYSE: HTGC). The proceeds will be used to fund the $3.4 million upfront cash payment associated with Celsion's acquisition of EGEN, Inc., which was announced separately today, as well as Celsion's transaction costs associated with the EGEN transaction.
Celsion Corporation to Acquire EGEN, Inc.
PR Newswire - Tue Jun 10, 6:30AM CDT
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas(TM) for delivery of DNA and mRNA, TheraSilence(TM) for delivery of RNA, and RAST(TM) for Cell Enabled Expression and Secretion of RNA.
Update on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:00PM CDT
Celsion (CLSN) received regulatory clearance to initiate the OPTIMA study on ThermoDox.
Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Wed May 21, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan, Hong Kong, South Korea and Canada. The OPTIMA Study is the Company's planned global pivotal, double-blind, placebo-controlled study evaluating ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA), in primary liver cancer, also known as hepatocellular carcinoma (HCC).
Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update
PR Newswire - Thu Mar 13, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
PR Newswire - Thu Mar 06, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2013 financial results at 11:00 a.m. EST on Thursday, March 13, 2014. To participate in the call, interested parties may dial 1-888-572-7033 (Toll-Free/North America) or 1-719-325-2469 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2013 Conference Call (Conference Code: 6632100) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer
PR Newswire - Thu Feb 27, 3:05PM CST
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). These data are consistent with the previously reported positive Phase 1 data in RCWBC.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
